ABBV-400 for Advanced Solid Tumors

What is the Purpose of this Study?

We are doing this study to find the best dose of the study drug, ABBV-400, and to see if it is a safe and effective option for treating cancer.

What is the Condition Being Studied?

Advanced Solid Tumors

Who Can Participate in the Study?

Adults ages 18+ who:

  • Are diagnosed with an advanced form of cancer
  • Have not seen improvement from standard therapies

For more information about who can join this study, please contact the study team at 919-668-1861.

Age Group
Adults

What is Involved?

If you choose to join this study, you will:

  • Get IV infusions of the study drug every 3 weeks for up to 2 years
  • Give blood and urine samples
  • Have regular CT or MRI scans

Study Details

Full Title
[M21-404] A Phase 1 first in human study evaluating safety, pharmacokinetics and efficacy of ABBV-400 as monotherapy and in combination with bevacizumab in adult subjects with advanced solid tumors
Principal Investigator
Headshot of John Strickler
Professor of Medicine
Protocol Number
IRB: PRO00111582
NCT: NCT05029882
Phase
Phase I
ClinicalTrials.gov
Enrollment Status
OPEN TO ACCRUAL
Participate